Citadel Advisors
AXDX

Citadel Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Citadel Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,200
Closed -$7.15K – 12511
2025
Q1 		$7.15K Buy
10,200
+10,000
+5,000% +$11.4K ﹤0.01% 13705
2024
Q4 		$240 Buy
+200
New +$332 ﹤0.01% 14361
2023
Q3 		– Sell
-230
Closed -$1.86K – 14269
2023
Q2 		$1.86K Sell
230
-360
-61% -$2.7K ﹤0.01% 13862
2023
Q1 		$4.13K Sell
590
-160
-21% -$962 ﹤0.01% 13981
2022
Q4 		$5.29K Sell
750
-2,680
-78% -$29.3K ﹤0.01% 14018
2022
Q3 		$52K Buy
3,430
+440
+15% +$7.28K ﹤0.01% 11593
2022
Q2 		$30K Buy
2,990
+1,760
+143% +$15.6K ﹤0.01% 12218
2022
Q1 		$18K Buy
1,230
+30
+3% +$854 ﹤0.01% 13267
2021
Q4 		$63K Buy
1,200
+160
+15% +$8.91K ﹤0.01% 13107
2021
Q3 		$61K Buy
1,040
+10
+1% +$652 ﹤0.01% 13252
2021
Q2 		$83K Sell
1,030
-300
-23% -$23.9K ﹤0.01% 13051
2021
Q1 		$111K Sell
1,330
-650
-33% -$65.9K ﹤0.01% 12381
2020
Q4 		$150K Sell
1,980
-1,370
-41% -$123K ﹤0.01% 9941
2020
Q3 		$357K Sell
3,350
-5,580
-62% -$775K ﹤0.01% 7845
2020
Q2 		$1.35M Buy
8,930
+7,040
+372% +$694K ﹤0.01% 5273
2020
Q1 		$157K Buy
1,890
+10
+0.5% +$1.41K ﹤0.01% 8251
2019
Q4 		$318K Buy
1,880
+360
+24% +$59.4K ﹤0.01% 7498
2019
Q3 		$282K Sell
1,520
-5,880
-79% -$1.14M ﹤0.01% 7641
2019
Q2 		$1.69M Buy
7,400
+590
+9% +$115K ﹤0.01% 4804
2019
Q1 		$1.43M Sell
6,810
-300
-4% -$56.2K ﹤0.01% 4984
2018
Q4 		$818K Buy
7,110
+1,640
+30% +$243K ﹤0.01% 5601
2018
Q3 		$1.25M Buy
5,470
+3,590
+191% +$794K ﹤0.01% 5155
2018
Q2 		$419K Sell
1,880
-1,810
-49% -$405K ﹤0.01% 6664
2018
Q1 		$843K Sell
3,690
-900
-20% -$236K ﹤0.01% 5061
2017
Q4 		$1.2M Buy
4,590
+2,320
+102% +$544K ﹤0.01% 4391
2017
Q3 		$510K Sell
2,270
-250
-10% -$61.4K ﹤0.01% 5292
2017
Q2 		$689K Sell
2,520
-90
-3% -$24.4K ﹤0.01% 4654
2017
Q1 		$632K Buy
2,610
+940
+56% +$215K ﹤0.01% 4669
2016
Q4 		$347K Sell
1,670
-780
-32% -$185K ﹤0.01% 5464
2016
Q3 		$668K Buy
+2,450
New +$542K ﹤0.01% 4403
2016
Q1 		– Sell
-900
Closed -$193K – 6762
2015
Q4 		$193K Sell
900
-620
-41% -$113K ﹤0.01% 5848
2015
Q3 		$246K Sell
1,520
-1,750
-54% -$379K ﹤0.01% 5849
2015
Q2 		$844K Sell
3,270
-440
-12% -$105K ﹤0.01% 4207
2015
Q1 		$835K Buy
3,710
+2,900
+358% +$606K ﹤0.01% 4172
2014
Q4 		$155K Sell
810
-700
-46% -$150K ﹤0.01% 6258
2014
Q3 		$324K Sell
1,510
-440
-23% -$85.6K ﹤0.01% 5169
2014
Q2 		$507K Buy
1,950
+1,140
+141% +$249K ﹤0.01% 4364
2014
Q1 		$177K Buy
+810
New +$120K ﹤0.01% 5635

Other funds holding AXDX

BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

Citadel Advisors's AXDX Position: Q2 2025 in Review

Citadel Advisors sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 23,451 shares — an estimated $16.4K sold.

Citadel Advisors first reported a position in AXDX in Q2 2014 and held it in 32 quarters. The position peaked at $2.38M in Q4 2019. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

  • Citadel Advisors reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 23,451 Accelerate Diagnostics shares in Q2 2025, an estimated $16.4K.
  • Citadel Advisors first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 32 quarters.
  • Citadel Advisors's Accelerate Diagnostics position peaked at $2.38M in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.